PBM
KURA icon

Propel Bio Management’s Kura Oncology KURA Stock Holding History

Propel Bio Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-130,000
Closed -$1.13M – 22
2024
Q4 		$1.13M Hold
130,000
– – 1.12% 14
2024
Q3 		$2.54M Hold
130,000
– – 1.47% 14
2024
Q2 		$2.68M Hold
130,000
– – 1.74% 15
2024
Q1 		$2.77M Hold
130,000
– – 1.61% 13
2023
Q4 		$1.87M Buy
+130,000
New +$1.28M 1.55% 20

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Propel Bio Management's KURA Position: Q1 2025 in Review

Propel Bio Management sold out of Kura Oncology (KURA) in Q1 2025, closing a stake of 130,000 shares — an estimated $1.13M sold.

Propel Bio Management first reported a position in KURA in Q4 2023 and held it in 5 quarters. The position peaked at $2.77M in Q1 2024. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

  • Propel Bio Management reported no remaining Kura Oncology position as of Q1 2025 after selling out during the quarter.
  • Propel Bio Management sold 130,000 Kura Oncology shares in Q1 2025, an estimated $1.13M.
  • Propel Bio Management first reported a position in Kura Oncology in Q4 2023 and held it in 5 quarters.
  • Propel Bio Management's Kura Oncology position peaked at $2.77M in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Propel Bio Management's 13F filing for Q1 2025, filed 15 May 2025.